![Epinephrine market size and share for anaphylaxis treatment [2032]](https://i0.wp.com/cdn.pixabay.com/photo/2020/10/11/12/59/kitesurfing-5645830_960_720.jpg?fit=%2C&ssl=1 "Epinephrine market size and share for anaphylaxis treatment [2032]")
The global epinephrine for anaphylaxis treatment market size was valued at USD 1.56 billion in 2023. The market is expected to grow from USD 1.67 billion in 2024 to USD 3.32 billion by 2032, registering a CAGR of 9.0% during the forecast period.
Anaphylaxis is one of the most serious, acute and life-threatening allergic diseases and is often underdiagnosed and inadequately managed. Food allergies, bee sting allergies, and pollen are some of the substances that cause anaphylactic shock. Anaphylaxis occurs within seconds or minutes after exposure to an allergic substance such as peanuts, bee stings, or sometimes a drug-induced reaction. In these situations, the immune system releases numerous chemicals that immediately cause skin rashes, nausea, vomiting, shock, a drop in blood pressure, sudden narrowing of the airways, and respiratory failure. Therefore, due to this serious condition, anaphylaxis should be treated immediately with epinephrine injection. It can be fatal.
As the burden of allergies and anaphylaxis increases globally, there is a growing demand for accurate, portable and easy-to-use epinephrine syringes for rapid onset of action to reduce the serious conditions associated with them. This scenario is fueling the market growth.
Moreover, the presence of major market players offering branded and generic products of epinephrine auto-injectors is expected to boost the global growth of the epinephrine for anaphylaxis treatment market. Increasing investment in research and development activities to develop new and advanced drug delivery systems for epinephrine for effective treatment of anaphylactic reactions further supports industry expansion.
- For example, in December 2023, Aquestive Therapeutics, Inc. announced that the first patient had been dosed in an initial Phase 3 central pharmacokinetic (PK) clinical trial of Anaphylm (epinephrine) Sublingual Film. This product is indicated for the treatment of serious, life-threatening allergic reactions, including anaphylaxis. These clinical studies will fuel the market growth.
In 2020, the global anaphylaxis treatment epinephrine market recorded negative growth due to a decrease in patient visits and hospitalizations in the early stages of the COVID-19 pandemic. This has led to a decline in anaphylaxis treatment prescriptions. However, with the easing of COVID-19 restrictions, the market began to grow with increasing patient visits for anaphylaxis treatment from late 2021.
Moreover, increasing demand for appropriate treatment options is expected to drive the market during the forecast period. Additionally, the market growth is expected to accelerate over 2024-2032 due to increasing number of prescriptions and increasing research and development initiatives to launch advanced delivery systems for anaphylaxis treatment.
Epinephrine for Anaphylaxis Treatment Market Trends
The emergence of new treatments for anaphylaxis is a notable trend.
The prevalence of anaphylaxis is rapidly increasing worldwide. To meet the growing demand for epinephrine, market players are focusing on introducing innovative products that offer new routes of administration.
Additionally, we are increasing our research and development activities on epinephrine, the leading anaphylaxis treatment company, bringing to market new, faster drug delivery systems for epinephrine delivery in anaphylactic conditions. The objective of this scenario is to promote market growth during the forecast period.
- For example, in June 2024, Aquestive Therapeutics, Inc. announced positive topline pharmacokinetic data from a temperature/pH study following a self-administration study of Anafilm (epinephrine) sublingual film. If approved by the U.S. Food and Drug Administration (FDA), Anafilm will be the first and only orally administered noninvasive epinephrine to treat serious, life-threatening allergic reactions, including anaphylaxis.
These advancements in drug delivery systems are expected to improve patient outcomes and shift corporate focus to product launches over the forecast period.
Request a Free Sample To learn more about this report.
Epinephrine for Anaphylaxis Treatment Market Growth Factors
Increasing prevalence of anaphylaxis in the general population increases demand for epinephrine
Anaphylaxis is a life-threatening acute hypersensitivity disorder, a rapidly progressing multi-organ allergic reaction. Anaphylaxis progresses rapidly to difficulty breathing, so it is often fatal if not treated in time. Common allergens that cause anaphylaxis are certain medications, foods, or insect stings. This increases the number of patients suffering from the condition and therefore the demand for epinephrine to treat emergency conditions.
- According to a paper published by the National Institutes of Health (NIH) in 2023, the worldwide incidence of anaphylaxis was found to be approximately 46 people per 100,000 people per year. This increasing number of cases is driving the demand for rapid and accurate therapeutic methods to treat anaphylaxis, which is expected to fuel the market growth.
Additionally, increasing awareness programs on allergy management and treatment using epinephrine syringes is expected to increase adoption of epinephrine for anaphylaxis treatment and boost market growth.
Increasing Reimbursement for Epinephrine Injections Drives Market Growth
The growing need for superior treatments for anaphylaxis to reduce hospitalization rates for chronic symptoms is driving the introduction of epinephrine auto-injectors. However, the cost of epinephrine pens is higher and inaccessible to many patients. Therefore, government agencies are providing reimbursement to ensure that people have access to epinephrine pens.
- Medicare prescription drug plans include a generic version of EpiPen epinephrine, according to a 2022 article published by Oak Street Health. Additionally, some other insurance policies cover branded versions of the EpiPen in the United States.
These policies are driving the adoption of epinephrine pens and boosting market growth.
constraints
Product recalls and legal violations for epinephrine syringes may hinder market growth
Despite the growing demand for anaphylaxis treatment, epinephrine syringe product launches are increasing. Recalls involving epinephrine syringes are increasing due to potential manufacturing defects leading to inaccurate dose delivery. Such a scenario is expected to lead to a decline in consumer confidence and hinder the market growth.
- In April 2023, Bausch Health, Canada Inc. recalled Emerade epinephrine autoinjectors 0.3 mg (DIN 02458446) and 0.5 mg (DIN 02458454) due to possible device failure.
Additionally, violations of certain laws related to EpiPen auto-injectors may impact the investment strategies and brand image of major companies, thereby limiting the growth of the epinephrine for anaphylaxis treatment market.
Epinephrine for Anaphylaxis Treatment Market Segmentation Analysis
Type analysis by product
High demand for portable and easy-to-use treatments drives auto-injector segment growth
On the basis of product type, the market is segmented into automatic syringes, pre-filled syringes, and others.
The autoinjector segment held a dominant market share in 2023. The dominant share of this segment is due to the increasing incidence of anaphylaxis and the sudden onset of serious life-threatening anaphylactic reactions due to allergens. Therefore, in order to suppress symptoms associated with anaphylactic shock, there is a growing demand for efficient treatment that reduces chronic symptoms of allergic reactions. The auto-injector is easy to use, portable, and provides a rapid onset of action for anaphylactic shock. Moreover, the presence of major players in the market with branded and generic versions of epinephrine auto-injectors for the treatment of anaphylaxis is expected to boost the growth of the segment.
Additionally, increasing guidelines from regulatory agencies to prevent serious consequences due to allergies using auto-injectors are expected to boost the growth of the segment.
- For example, the Medicines and Healthcare products Regulatory Agency (MHRA) has strengthened its safety guidance on the appropriate actions to take in the event of anaphylaxis. The guidance was published following new figures showing 25,721 people were admitted to hospital due to allergies and anaphylaxis in England during 2022-23. The MHRA has also published guidance for recognizing and responding to signs of anaphylaxis, including the use of adrenaline auto-injectors (Epi-Pen and Jext products) prescribed to people at risk of anaphylaxis. These guidelines promote the growth of the sector.
The prefilled syringes segment held a significant share in the market. The growing number of hospitalizations related to allergies and anaphylaxis is further fueling the growth of this segment, increasing the demand for accurate and measured doses of epinephrine, providing convenience to healthcare professionals.
- For example, a November 2021 Australian Health and Care Quality Commission (ACSQHC) report found that from 2015 to 2020, there was a 51.0% increase in the number of patients admitted to emergency departments for treatment of anaphylaxis in public hospitals.
The Other segment is expected to grow at a steady CAGR during the forecast period. However, this segment is expected to hold a notable share of the market due to the increasing research and development activities by market key players to launch advanced and convenient drug delivery options of epinephrine for the treatment of anaphylactic reactions. These scenarios are expected to fuel the segment growth during the forecast period.
To find out how our reports can help you optimize your business, speak to an analyst
type analysis results
Increasing demand for cost-effective epinephrine to drive generic segment growth
Based on type, the market is segmented into branded products and generic products.
The generics segment held the highest market share for epinephrine for the treatment of anaphylaxis globally. The dominant share of this segment is due to the growing demand for cost-effective treatment options for anaphylaxis. Additionally, patent expiration of branded drugs has led to an increase in the manufacture of generic versions of epinephrine in the market. Therefore, to reduce epinephrine shortage and provide cost-effective options, major players in the market are focusing on launching generic epinephrine.
Additionally, growing interest from government agencies to reduce healthcare costs and provide convenient care to patients is expected to accelerate the growth of the sector.
- For example, according to an article presented at the Dubai International Pharmaceutical and Technology Conference and Exhibition (DUPHAT) in September 2022, the Saudi government has attempted to actively encourage generic consumption by restricting imported branded drugs and encouraging local generic manufacturing. Efforts to reduce health care costs and diversify the economy. These promotions promote the growth of this segment in the market.
The branded segment held a significant share of the market due to the presence of major players offering branded products of epinephrine for the treatment of anaphylaxis. Additionally, increasing research and development activities to launch new patented epinephrine formulations for easy and convenient treatment of sudden allergic reactions is expected to boost the growth of the segment.
By distribution channel analysis
Online and retail pharmacy segments recorded the highest share due to increased adoption of epinephrine injections.
Based on distribution channel, the market is segmented into online and retail pharmacies and hospital pharmacies.
Online and retail pharmacy segments held the dominant share in the market. The segment growth is attributed to accessibility, convenience and extensive distribution network. These pharmacies provide easy access to epinephrine auto-injectors for patients who need them, ensuring timely procurement of this important medication. The convenience of online pharmacies allows patients to purchase epinephrine at home by taking advantage of doorstep delivery. Additionally, both channels offer competitive pricing, number of discs, and claims options, making them attractive to customers.
Additionally, the number of e-pharmacies is increasing globally to facilitate drug sales, thereby accelerating the segment growth.
- For example, there are about 50 e-pharmacies in India, according to a July 2023 report by the India Brand Equity Foundation.
The hospital pharmacy segment accounted for a significant portion of the epinephrine for anaphylaxis treatment market. As patient preference for hospitals increases and the number of patients admitted to emergency rooms increases, the demand for rapid treatment through epinephrine injection is also increasing. Additionally, the presence of a large number of hospital pharmacies in the region is boosting the growth of the sector.
- For example, according to the 2013-2022 Drug Usage Statistics in the United States, the number of patients receiving epinephrine treatment in the United States in 2022 was estimated at 992,912. This large patient volume is expected to fuel the growth of epinephrine therapy. It’s a segment.
local insight
By region, the Epinephrine for Anaphylaxis Treatment market has been studied across Europe, North America, Asia Pacific, Latin America, Middle East, and Africa.
North America Epinephrine for Anaphylaxis Treatment Market Size, 2023 (USD Billion)
To get detailed information on regional analysis of this market, Request Free Sample
North America held the highest share of the market, generating revenue of USD 1.06 billion in 2023. The increasing prevalence of anaphylaxis and allergies is increasing its dominant share in this region. The region also has state-of-the-art medical facilities and strong healthcare spending for the treatment of chronic anaphylactic disease. Additionally, increasing research and development plans by major companies to launch new epinephrine formulations for the treatment of anaphylaxis is expected to fuel the market growth.
- For example, in March 2024, Aquestive Therapeutics, Inc. announced key clinical results from its Phase 3 central pharmacokinetics (PK) clinical trial for Anaphylm (epinephrine) sublingual film. The sublingual film successfully met the trial’s primary and secondary endpoints. These clinical trials are expected to boost the growth of this region in the market.
Asia Pacific region holds the second largest market share. Growth in this region is due to a larger patient pool, increasing prevalence of allergies and increased demand for epinephrine for the treatment of anaphylaxis. Additionally, growing strategic initiatives by market companies to expand their geographical presence through commercial launch of epinephrine injectables in the region is expected to boost regional growth.
- For example, in October 2019, DMK Pharmaceuticals entered into an exclusive distribution and commercialization agreement with Emerge Health Pty to commercialize SYMJEPI (epinephrine) injectable product in Australia and New Zealand.
Europe holds a significant share of this market. Growing demand for fast and accurate emergency treatment options for anaphylaxis and presence of major players increasingly focusing on research and development to launch branded and generic versions of drugs are boosting the growth in this region during the forecast period.
Latin America, Middle East and Africa accounted for relatively low market share due to lack of regulatory approval for epinephrine syringes in the region and high costs associated with auto-injectors. However, rising initiatives and awareness programs regarding anaphylaxis management are expected to fuel the market growth over the forecast period.
- For example, in June 2024, the Argentine Society of Allergy and Clinical Immunology participated in the Conference on Environment, Allergy and Respiratory Diseases to discuss causes and treatments related to allergies. These meetings drive epinephrine adoption and drive regional growth.
major industry players
Viatris Inc. launches branded and generic auto-injectors from Teva Pharmaceutical Industries Ltd to strengthen market presence
The global epinephrine market for the treatment of anaphylaxis is consolidated. Viatris Inc. and Teva Pharmaceutical Industries Ltd. are among the market leaders due to their strong brand awareness and recent product approvals. The company’s growing focus on regulatory approvals and generic product launches has led to the company’s highest share in the market.
Additionally, other players participating in the market include Amneal Pharmaceuticals LLC., ALK-Abelló A/S, kaleo, DMK Pharmaceuticals, and Bausch Health Companies Inc. The company is focused on mergers and acquisitions and launching new technologically advanced products. It is driving market growth.
List of best epinephrine for anaphylaxis treatment companies:
- Viatris Inc. (USA)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Adamis Pharmaceuticals LLC. (Canada)
- Bausch Health Companies Inc.(미국)
- Amneal Pharmaceuticals LLC (USA)
- DMK Pharmaceuticals (USA)
- ALK-Abelló A/S (Denmark)
- BIOPROJET (France)
major industrial developments
- May 2023: DMK Pharmaceuticals announces merger with DMK Pharmaceuticals Corporation. The purpose of this merger is to commercialize products and develop new drug candidates.
- July 2021: ALK-Abelló A/S, in partnership with Grand Pharmaceutical Group Limited, launched Jext, China’s first adrenaline auto-injector, to expand its geographic presence in China.
- October 2020: Bausch Health Companies Inc. launched Emerade, an epinephrine injection in doses of 0.3 mg and 0.5 mg, in Canada for the emergency treatment of anaphylactic reactions in patients. The launch of this product creates a new treatment option for anaphylaxis in Canada.
- October 2018: Amneal Pharmaceuticals LLC worked with the U.S. Food and Drug Administration (FDA) to extend the expiration date for certain lots of Epinephrine Injection, USP Auto-Injector, 0.15 mg and 0.3 mg Adrenaclick. .
report scope
The global market report provides detailed information about the competitive environment of the market. This includes statistics such as anaphylaxis prevalence. Additionally, the report consists of a market overview including value, size, volume, and share of the market segments. Additionally, the global market analysis report focuses on key points such as technological advancements, new product launches, partnerships, and key industry developments such as mergers and acquisitions. It also provides regional analysis of various segments, profiles of key market players, trends, and the impact of COVID-19 on the market. The report also consists of quantitative and qualitative insights that contribute to market growth.
Get comprehensive insights into the market, request customization
![Ahn Young-mi, the reason for breaking up with her ‘best friend’ Kang Yu-mi…Kim Gura also ‘bowed down’ (Kim Gura Show)[종합]](https://i0.wp.com/news.koreadaily.com/data/photo/2024/10/18/202410171629771664_6710c7b5a8424.jpg?resize=150%2C150&ssl=1 "Ahn Young-mi, the reason for breaking up with her ‘best friend’ Kang Yu-mi…Kim Gura also ‘bowed down’ (Kim Gura Show)[종합]")
